Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Ruxolitinib

First Posted Date: 2008-03-19

Last Posted Date: 2018-02-12

Lead Sponsor: Incyte Corporation

Target Recruit Count: 22

Registration Number: NCT00638378

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Ruxolitinib

First Posted Date: 2008-02-18

Last Posted Date: 2022-02-08

Lead Sponsor: Incyte Corporation

Target Recruit Count: 25

Registration Number: NCT00617994

A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: INCB018424
Drug: Placebo

First Posted Date: 2007-10-26

Last Posted Date: 2015-03-23

Lead Sponsor: Incyte Corporation

Target Recruit Count: 50

Registration Number: NCT00550043

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Phase 1

Completed

Conditions: Polycythemia Vera
Thrombocytosis
Myelofibrosis

Interventions: Drug: Ruxolitinib

First Posted Date: 2007-08-01

Last Posted Date: 2018-03-12

Lead Sponsor: Incyte Corporation

Target Recruit Count: 154

Registration Number: NCT00509899

Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2
Obesity

Interventions: Drug: INCB013739
Drug: Placebo

First Posted Date: 2007-05-24

Last Posted Date: 2016-12-06

Lead Sponsor: Incyte Corporation

Target Recruit Count: 24

Registration Number: NCT00478322

A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes

Phase 1

Completed

Conditions: Insulin Resistance
Obesity

First Posted Date: 2006-11-14

Last Posted Date: 2012-01-23

Lead Sponsor: Incyte Corporation

Registration Number: NCT00398619

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: INCB009471
Drug: Placebo comparator

First Posted Date: 2006-10-26

Last Posted Date: 2018-03-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 45

Registration Number: NCT00393120

Randomized, Double-Blind Study Comparing Dexelvucitabine (DFC) to Lamivudine (3TC) in Subjects With Resistance to NRTIs, PIs, and NNRTIs

Phase 2

Terminated

Conditions: Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: Dexelvucitabine

First Posted Date: 2006-03-09

Last Posted Date: 2018-08-23

Lead Sponsor: Incyte Corporation

Target Recruit Count: 250

Registration Number: NCT00300573

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy